Brentuximab vedotin and anti‐PD1 treatment optimize survival in chemo‐refractory Hodgkin lymphoma patients: Real‐world data. Issue 4 (24th July 2019) - Sakellari, Ioanna; Gavriilaki, Eleni; Iskas, Michail; Bousiou, Zoi; Chatziioannidis, Aristotelis; Batsis, I.; Mallouri, Despina; Constantinous, Varnavas; Stavroyianni, Niki; Syrigou, Antonia; Marvaki, Anastasia; Pilavaki, Maria; et al.